Table 2.

The frequency of treatment-related toxic effects in 38 treated patients with gastric or gastroesophageal junction cancer expressed as the worst toxicity per patient

Toxicity type	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4, n (%)
Bevacizumab related
GI perforation	0 (0)	0 (0)	1 (3)	2 (5)
Tracheoesophageal fistula	0 (0)	0 (0)	0 (0)	1 (3)
Hypertension	4 (11)	1 (3)	2 (5)	0 (0)
Venous thromboembolism	1 (3)	0 (0)	1 (3)	0 (0)
Proteinuria	1 (3)	1 (3)	0 (0)	0 (0)
Hematological
Neutropenia	0 (0)	1 (3)	5 (13)	8 (21)
Anemia	1 (3)	2 (5)	0 (0)	0 (0)
Leukopenia	2 (5)	0 (0)	1 (3)	0 (0)
Neuropathy
Acute	3 (8)	6 (16)	2 (5)	0 (0)
Chronic	5 (13)	0 (0)	3 (8)	0 (0)
GI-related toxic effects
Stomatitis	1 (3)	0 (0)	0 (0)	0 (0)
Nausea	7 (18)	3 (8)	4 (11)	0 (0)
Vomiting	3 (8)	1 (3)	2 (5)	0 (0)
Diarrhea	7 (18)	5 (13)	3 (8)	0 (0)
Hepatotoxicity
Aspartate transaminase	1 (3)	0 (0)	0 (0)	0 (0)
Alanine transferase	1 (3)	0 (0)	0 (0)	0 (0)
Alkaline phosphatase	0 (0)	1 (3)	0 (0)	0 (0)
Other
Dehydration	0 (0)	0 (0)	4 (11)	0 (0)
Fever	1 (3)	0 (0)	2 (5)	0 (0)
Infection	0 (0)	1 (3)	0 (0)	0 (0)
Fatigue	7 (18)	7 (18)	2 (5)	0 (0)
Anorexia	2 (5)	1 (8)	2 (5)	0 (0)
Myalgia	1 (3)	0 (0)	0 (0)	0 (0)
Alopecia	0 (0)	1 (3)	0 (0)	0 (0)

Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 scale for toxicity grading.

GI, gastrointestinal.